Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . ATLANTA — The standard approach of maintaining hematocrit levels less than 45% in patients with polycythemia ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events compared with a higher ...

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

Atlanta, GA - Maintaining a lower hematocrit (HCT) can help reduce the risk of cardiovascular death in patients with polycythemia vera, according to the results of CYTO-PV [1]. Those who had an HCT of ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...

Use of dried blood or dried matrix spotting for assessment of hematocrit has become a popular laboratory method. However, the procedure may adversely affect the hematocrit values and thus interfere ...